AI Engine Delivers Engagement Gains as Recurring Revenue Outlook Climbs

1. DarioHealth Corp. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
2. James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
3. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

DarioHealth Corp. (DRIO:NASDAQ) announced that it expects broader deployment of DarioIQ, its proprietary responsible generative and agentic AI platform, to increase annual Business-to-Business-to-Consumer (B2B2C) recurring revenue from existing customers by approximately 10% to 15%, before the impact of future customer wins or additional condition expansions.  The announcement comes as digital health continues to rotate toward AI-driven platforms and the broader AI transformation into healthcare remains a focus across the sector.

According to the company, DarioIQ is designed to increase member engagement, retention, and clinical outcomes, supporting its existing B2B2C customer base. The company said DarioIQ increased active member engagement by 40% and improved member retention by 20% compared with a control group through personalized interventions tailored to each member's health profile and behavior. Dario stated these results reflect DarioIQ development completed during the first half of 2026.

Dario said its multi-condition platform continues to support its land-and-expand strategy with enterprise customers and that DarioIQ provides an additional opportunity to increase recurring revenue from current clients. The company stated that higher engagement and retention support its previously reported return on investment of 2.5X to 5X across its programs.

"Higher engagement increases the lifetime value of members while improving customer ROI, enabling Dario to grow revenue without proportionally increasing customer acquisition costs," Lara Dodo, Chief Operating Officer of Dario, said in a company news release.

The company said DarioIQ is powered by a de-identified dataset of more than 13 billion proprietary real-world healthcare data points collected through its business-to-consumer experience. According to Dario, the platform combines biometric readings from U.S. Food and Drug Administration-cleared connected devices, clinical history, and member behavioral engagement patterns to determine personalized communications for individual members. The company said DarioIQ operates with human and clinical oversight, privacy safeguards, and continuous monitoring.

"AI is transforming healthcare, and we believe Dario is well-positioned to lead the industry in harnessing the power of one of the largest proprietary datasets to improve outcomes for patients and payers," Erez Raphael, Chief Executive Officer of Dario, said in a company news release. "In managing chronic health, Dario owns the whole stack. We own the devices, the data, and the AI built over more than a decade. DarioIQ turns that integrated stack into results we can measure for members and for the clients who pay for outcomes."

AI Adoption Continued Across Healthcare

According to a June 24 report from Grand View Research, the global artificial intelligence in healthcare market was estimated at US$36.7 billion in 2025 and was projected to grow from US$50.7 billion in 2026 to US$505.6 billion by 2033. The report stated that "the increasing demand for advanced healthcare technologies, rising adoption of artificial intelligence-driven clinical decision support systems, growing healthcare data volumes, and the need for improved patient outcomes" had accelerated AI integration across healthcare. It also wrote that AI was "emerging as a transformative technology" by enabling "faster diagnosis, improved treatment planning, operational efficiency, and enhanced patient engagement."

Zion Market Research wrote on July 6 that the global generative AI in healthcare market was valued at approximately US$1.84 billion in 2024 and was projected to reach US$21.64 billion by 2034. The firm stated that generative AI technologies were "transforming healthcare by producing novel solutions tailored to specific medical needs," supporting diagnostics, treatment planning, and operational efficiency. It also said demand was being driven by physician burnout, clinically validated performance, increasing investment, and "accelerating digitalization with improved EHR data availability."

AI Execution and Commercial Momentum Drew Continued Support

In a July 5 digital health report, Stifel Managing Director David M. Grossman highlighted continued strength across the digital health sector as the firm's Digital Health Index gained 11% during the week, outperforming the Bloomberg 2000 Growth Index, which was flat. Stifel noted the index had risen 56% over the previous 90 days, compared with a 19% gain for the broader growth benchmark, outperforming by approximately 3,700 basis points.

The firm said trading during the holiday-shortened week was "largely driven by sentiment surrounding AI announcements (+/-), rotation out of semiconductors (+), and company-specific news (+/-)." Stifel also reported that valuation multiples continued to expand across digital health, with the Virtual Care and Remote Patient Monitoring group trading at 2.4x next-12-month enterprise value-to-revenue as of July 2, up from 1.5x 90 days earlier.

Stifel also pointed to growing adoption of artificial intelligence in healthcare, citing survey data showing that "roughly three in ten adults self-reported turning to social media (31%) or AI chatbots (29%) at least monthly for health information and advice." Among AI users, the firm noted that "wanting quick or immediate advice (65%)" was the most common reason for using AI, while many respondents also reported consulting AI before deciding whether to seek care from a healthcare provider.

Within the report, Stifel highlighted DarioHealth's expanded relationship with a national health plan, its strategic collaboration with Beluga Health, and the appointment of former Humana Chief Compliance Officer Sean O'Reilly to its advisory board. The firm maintained its Buy rating and US$7.28 price target on the company.

CG Capital also reiterated its Outperform rating and US$28.00 price target following DarioHealth's first quarter results. In its May 13 research update, the firm cited a second consecutive quarter of sequential revenue growth, lower operating expenses, continued commercial pipeline expansion, new customer additions, and approximately US$13 million in contracted and late-stage business progressing through implementation. CG Capital also highlighted early DarioIQ data showing up to a 40% improvement in member retention and up to a 57% increase in active sessions compared with a control group.

In earlier research published May 12, CG Capital wrote that DarioHealth had consolidated "four formerly separate digital health businesses (diabetes, hypertension, MSK, behavioral health) onto a single technology and commercial chassis under the DarioIQ AI architecture." The firm also noted that the platform now addresses more than six chronic conditions through a single member experience and cited more than 100 peer-reviewed studies supporting the platform.

AI Platform Expansion and Digital Health Initiatives

Dario's July 2026 corporate presentation states that the company is leveraging more than 13 billion proprietary data points and AI across its digital health platform. The presentation describes DarioIQ as an AI engine operating on proprietary real-world clinical data collected through connected devices and member interactions.

According to the presentation, DarioIQ is currently used to personalize content, timing, and communication channels for individual members, trigger behavior-based interventions, and improve engagement and retention. The company also states that the AI platform is being applied across product development, clinical operations, customer support, finance, client reporting, and member engagement workflows to improve operating efficiencies. 

The presentation also describes Dario's expansion into provider-backed care, which the company said connects AI-driven engagement with clinical intervention. According to the company, the expanded offering includes a national clinical infrastructure, a 50-state provider network, prescribing capabilities, diagnostic testing, and escalation from AI-supported engagement to clinician care. The company said the same AI engine can support a broader range of clinical workflows, provider interactions, and reimbursement opportunities as it expands into larger healthcare markets.

Ownership and Share Information¹

DarioHealth Corp. has a market cap of US$51.41 million, with 7.3 million shares outstanding.

The company's 52-week range is US$5.84-US$17.74.

Institutions own 39.4% of shares, while Strategic Investors own 7.5%.

Management & Insiders own 4.5% of shares, and the remaining 48.6% of shares are held by Retail.